Trial Profile

A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (obinutuzumab), Acalabrutinib (ACP-196) and ABT-199 (venetoclax) in Patients with Relapsed/refractory CLL (CLL2-BAAG Protocol)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms CLL2-BAAG

12 Dec 2023 Results assessing efficacy data and circulating tumor DNA (ctDNA) analyses with additional follow-up, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
14 Nov 2023 Status changed from active, no longer recruiting to completed.
01 Nov 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com